Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
The human microbiome market is projected to expand at a CAGR of 20.42%, growing from $941.215 million in 2025 to $2.38 billion by 2030. This growth is driven by rising lifestyle...
Wall Streets main indexes were on track for a lower open on Tuesday as the Israel-Iran conflict entered its fifth day, denting global investor confidence ahead of the Federal...
The mean of analysts price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective,...
